SCHEMBL3159978

SCHEMBL3159978

NC(=O)c1ccccc1C[CH]c1cccc(-c2ccccc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT1 Q96EB6 2/20 0.46
SIRT2 Q8IXJ6 1/20 0.46
IKBKB O14920 2/20 0.45
TRIM24 O15164 1/20 0.43
TRIM33 Q9UPN9 1/20 0.43
BCAT2 O15382 1/20 0.42
PARP1 P09874 3/20 0.42
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
HPGD P15428 2/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
DHODH Q02127 1/20 0.40
BCL2L1 Q07817 1/20 0.39
BAD Q92934 1/20 0.39
PTGER1 P34995 1/20 0.38
PTGER4 P35408 1/20 0.38
PTGER3 P43115 1/20 0.38
PTGER2 P43116 1/20 0.38
PRSS1 P07477 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4101513 0.86 KDM4E (0.47) SIRT1SIRT2BCAT2PARP1KDM4E
SCHEMBL3173779 0.84 PARP1 (0.44) IKBKBPARP1KDM4EALDH1A1DHODH
SCHEMBL3174393 0.81 CYP11B2 (0.45) BCL2L1BAD
SCHEMBL3174985 0.81 PARP1 (0.45) PARP1KDM4EALDH1A1HPGDLMNA
SCHEMBL3170684 0.81 MAP4K4 (0.36) IKBKBKDM4EALDH1A1HPGDAKR1C3
SCHEMBL3168792 0.81 JAK2 (0.50)
SCHEMBL4651184 0.80 BCAT2 (0.41) IKBKBBCAT2PARP1
SCHEMBL3170274 0.80 ITGB3 (0.38) SIRT1SIRT2PARP1
SCHEMBL3165470 0.80 CHEK1 (0.40)
SCHEMBL3170155 0.79 CYP11B1 (0.44) ALDH1A1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1841504-B1 SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-11-19 EP disclosed
US-7645799-B2 Substituted biaryl compounds as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-01-12 US disclosed
US-20090062287-A1 SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2009-03-05 US disclosed
US-7459564-B2 Substituted biaryl compounds as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-12-02 US disclosed
EP-1841504-A2 SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS Brystol-Myers Squibb Company (US) 2007-10-10 EP disclosed
WO-2006076575-A2 SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2006-07-20 WO disclosed
US-20060154915-A1 Substituted biaryl compounds as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY 2006-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060154915-A1 Substituted biaryl compounds as factor XIa inhibitors TFPI, F3, F12 SIRT1 2581/4885SIRT2 2856/4885IKBKB 101/4885
US-20090062287-A1 SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS TFPI, F3, F12 SIRT1 2581/4885SIRT2 2856/4885IKBKB 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.